**Name of Journal:** *World Journal of Experimental Medicine*

**Manuscript NO:** 85135

**Manuscript Type:** LETTER TO THE EDITOR

**Update on hydroxychloroquine use in pregnancy**

Nori W *et al*. HCQ in pregnancy

Wassan Nori, Nabeeha Najatee Akram, Raid M Al-Ani

**Wassan Nori,** Department of Obstetrics and Gynecology, Mustansiriyah University, Baghdad 10052, Iraq

**Nabeeha Najatee Akram,** Department of Pediatrics, Mustansiriyah University, Baghdad 10052, Iraq

**Raid M Al-Ani,** Department of Surgery/Otolaryngology, University of Anbar, Anbar 31001, Iraq

**Author contributions:** Nori W and Akram NN designed research and analyzed data; Nori W wrote the letter; Akram NN and Al-Ani RM revised the letter; All authors have read and agreed on the final version of the manuscript.

**Corresponding author: Wassan Nori, PhD, Academic Editor, Academic Research, Senior Researcher,** Department of Obstetrics and Gynecology, Mustansiriyah University, No. 58 Al-amin Street, Baghdad 10052, Iraq. dr.wassan76@uomustansiriyah.edu.iq

**Received:** April 13, 2023

**Revised:** July 5, 2023

**Accepted:** July 24, 2023

**Published online:** September 20, 2023

**Abstract**

It is well-known that hydroxychloroquine (HCQ) treats malaria, systemic lupus erythematosus, and rheumatoid arthritis in women for its immunomodulatory and anti-inflammatory action. Additionally, HCQ was used in cases with refractory antiphospholipid syndrome. HCQ safety was reinforced in pregnant women owing to insignificant reports of adverse pregnancy outcomes and major congenital malformation. Recently, HCQ was tested in cases with chronic placental inflammation with a promising result of increased life birth; however, its benefit needs further validation. We aimed to highlight the recent updates for HCQ use in various conditions in pregnancy.

**Key Words:** Pregnancy; Hydroxychloroquine; Preeclampsia; Antiphospholipid syndrome; Chronic placental inflammation; COVID-19

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Nori W, Akram NN, Al-Ani RM. Update on hydroxychloroquine use in pregnancy. *World J Exp Med* 2023; 13(4): 99-101

**URL**: https://www.wjgnet.com/2220-315x/full/v13/i4/99.htm

**DOI**: https://dx.doi.org/10.5493/wjem.v13.i4.99

**Core Tip:** The immunomodulatory, anti-inflammatory, and anti-thrombotic activity of hydroxychloroquine (HCQ), an anti-malarial drug, made it recommendable for rheumatoid arthritis and systemic lupus erythematosus. HCQ was also implemented in refractory antiphospholipid syndrome showing a successful outcome. Recent evidence supports the benefits of its use to outweigh the risk during pregnancy as it reduces the disease activity and the associated adverse pregnancy outcome. Chronic placental inflammation is another condition for which HCQ proved to be helpful. Further investigations are required to verify HCQ’s efficacy in chronic placental inflammation as well as its action in reducing the severity of coronavirus disease 2019 in pregnant women.

**TO THE EDITOR**

With interest, we read the Bajpai *et al*[1]study published in the *World Journal of Experimental Medicine* (issue 3, volume 12, 2022) that discussed the role of hydroxychloroquine (HCQ) in treating high-risk groups with coronavirus disease 2019 (COVID-19). Indeed, HCQ gained much interest during the current pandemic owing to its anti-inflammatory and immunomodulatory effects[1].

HCQ had an update regarding its use among pregnant, first in autoimmune diseases and its safety profile-second, its therapeutic role in cases with chronic placental inflammation. Finally, we discuss its potential use in pregnant with COVID-19, which is worth mentioning and was not discussed by Bajpai *et al*’s study[1].

HCQ was already used for treating women suffering from malaria, systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA)[2]. In 2020, the American College for Managing SLE, RA for women of reproductive age, advised that those cases should receive HCQ before and throughout pregnancy[3]. In addition, pregnant women with refractory antiphospholipid syndrome may consider HCQ in addition to standard treatment (aspirin and low molecular weight heparin)[4].

HCQ was used as an adjunctive therapy for cases with refractory antiphospholipid syndrome[5]. It is a beneficial role proposed to be mediated *via* anti-thrombotic, antiplatelet, and immunomodulatory properties[6]. Others suggested that HCQ reduces endothelial dysfunction and improves vascular elasticity, thus improving blood flow[7].

Bérard *et al*’s study addressed pregnancy outcomes related to HCQ use in a cohort study that recruited 233748 pregnant women[8]. Interestingly the study showed that HCQ had a good safety profile. There was no increased risk of preterm labor among drug users; the adjusted odd ratio was 1.39, with respective 95% confidence interval (CI): 0.83 to 2.3. As for the low birth weight, the adjusted odd ratio was 1.12, 95%CI: 0.59 to 2.07. Finally, the adjusted odd ratio for major congenital malformation was 1.02, 95%CI: 0.68 to 1.53[8].

Another study confirmed no substantial rise in significant congenital malformations in newborns exposed to HCQ during the first trimester of pregnancy[9]. In line with earlier work[10,11]. These results reinforce that therapy advantage during pregnancy is likely to exceed the risks for the majority of patients with rheumatic disease.

Ye *et al*[12] discussed that HCQ application might alleviate the risk of high lupus activity during pregnancy and the incidence of preeclampsia. However, in their meta-analysis, Hu *et al*[13] found no value of HCQs in reducing preeclampsia in antiphospholipid syndrome. Moreover, HCQ had no value in reducing fetal growth defects in SLE and/or antiphospholipid cases.

The promising results observed with the use of HCQ to treat autoimmunity in pregnancy have laid the foundation for its use in chronic placental inflammation, a condition characterized by the disruption of healthy placental tissue. They can only be confirmed by a post-delivery histopathological examination[14]. Chronic placental inflammation has been linked to severe complications of pregnancy, such as fetal growth restriction, premature labor, and miscarriage[15].

Brady *et al*’s study examined the value of adding HCQ to pregnant women with a positive history of chronic placental inflammation, showing a decrease in disease severity and a trend for a higher live birth rate[16]. There are currently no prospective, informatively constructed, controlled trials on the efficacy of HCQs in these settings, which emphasizes the need for such work. Since some forms of chronic placental inflammation are recurrent, determining the cause is crucial for future pregnancies care.

The use of HCQ in COVID-19 cases will depend upon if the ongoing clinical trials demonstrate significant benefits of HCQ in reducing the incidence or severity of COVID-19[9,17,18]. Even though initial trials utilizing HCQ to treat COVID-19 failed to demonstrate efficacy, pre-exposure preventative trials are yet to be reported[9].

In conclusion, HCQ has demonstrated efficacy in mitigating the activity of autoimmune diseases and some of their adverse pregnancy outcomes while maintaining a favorable safety profile. HCQ has emerged as a potential therapeutic option for cases with chronic placental inflammation, as it enhances live birth rates while decreasing the severity of the associated disease. Nevertheless, the efficacy and safety of HCQ in pregnant individuals with COVID-19 have not been thoroughly assessed. Further research is needed to unveil more applications in practice.

**ACKNOWLEDGEMENTS**

To our beloved university, Mustansiriyah, for continuous support.

**REFERENCES**

1 **Bajpai J**, Pradhan A, Verma AK, Kant S. Use of hydroxychloroquine and azithromycin combination to treat the COVID-19 infection. *World J Exp Med* 2022; **12**: 44-52 [PMID: 35765514 DOI: 10.5493/wjem.v12.i3.44]

2 **Clowse MEB**, Eudy AM, Balevic S, Sanders-Schmidler G, Kosinski A, Fischer-Betz R, Gladman DD, Molad Y, Nalli C, Mokbel A, Tincani A, Urowitz M, Bay C, van Noord M, Petri M. Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. *Lupus Sci Med* 2022; **9** [PMID: 35318256 DOI: 10.1136/lupus-2021-000651]

3 **Sammaritano LR**, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, Marder W, Guyatt G, Branch DW, Buyon J, Christopher-Stine L, Crow-Hercher R, Cush J, Druzin M, Kavanaugh A, Laskin CA, Plante L, Salmon J, Simard J, Somers EC, Steen V, Tedeschi SK, Vinet E, White CW, Yazdany J, Barbhaiya M, Bettendorf B, Eudy A, Jayatilleke A, Shah AA, Sullivan N, Tarter LL, Birru Talabi M, Turgunbaev M, Turner A, D'Anci KE. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. *Arthritis Rheumatol* 2020; **72**: 529-556 [PMID: 32090480 DOI: 10.1002/art.41191]

4 **Nori W,** Shallal F, Zghair MAG. Aspirin effect on Mid luteal Phase Doppler Indices in Patients with Recurrent Pregnancy Loss. *Int J Pharm Res* 2020; **12**: 2929-2934 [DOI: 10.31838/ijpr/2020.12.03.413]

5 **Saraiva-Mangolin S**, Vaz CO, Ruiz T, Mazetto BM, Orsi FA. Use of hydroxychloroquine to control immune response and hypercoagulability in patients with primary antiphospholipid syndrome. *Eur J Intern Med* 2021; **90**: 114-115 [PMID: 34099368 DOI: 10.1016/j.ejim.2021.05.025]

6 **Urbanski G**, Caillon A, Poli C, Kauffenstein G, Begorre MA, Loufrani L, Henrion D, Belizna C. Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an *in vivo* mouse model of antiphospholipid syndrome. *PLoS One* 2018; **13**: e0206814 [PMID: 30399161 DOI: 10.1371/journal.pone.0206814]

7 **Dong Y**, Lu Y, Xia Y, Wang X. Effect of hydroxychloroquine on antiphospholipid antibodies-inhibited endometrial angiogenesis. *J Matern Fetal Neonatal Med* 2022; **35**: 7084-7092 [PMID: 34182874 DOI: 10.1080/14767058.2021.1943656]

8 **Bérard A**, Sheehy O, Zhao JP, Vinet E, Quach C, Bernatsky S. Chloroquine and Hydroxychloroquine Use During Pregnancy and the Risk of Adverse Pregnancy Outcomes Using Real-World Evidence. *Front Pharmacol* 2021; **12**: 722511 [PMID: 34408654 DOI: 10.3389/fphar.2021.722511]

9 **Huybrechts KF**, Bateman BT, Zhu Y, Straub L, Mogun H, Kim SC, Desai RJ, Hernandez-Diaz S. Hydroxychloroquine early in pregnancy and risk of birth defects. *Am J Obstet Gynecol* 2021; **224**: 290.e1-290.e22 [PMID: 32961123 DOI: 10.1016/j.ajog.2020.09.007]

10 **Liu J**, Zhang L, Tian Y, Wan S, Hu M, Song S, Zhang M, Zhou Q, Xia Y, Wang X. Protection by hydroxychloroquine prevents placental injury in obstetric antiphospholipid syndrome. *J Cell Mol Med* 2022; **26**: 4357-4370 [PMID: 35770338 DOI: 10.1111/jcmm.17459]

11 **Do SC**, Rizk NM, Druzin ML, Simard JF. Does Hydroxychloroquine Protect against Preeclampsia and Preterm Delivery in Systemic Lupus Erythematosus Pregnancies? *Am J Perinatol* 2020; **37**: 873-880 [PMID: 31899930 DOI: 10.1055/s-0039-3402752]

12 **Ye S**, Zhao X, Liu Y, Ma Y, Wang Y, Zhao J. The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities. *Clin Rheumatol* 2023; **42**: 1137-1150 [PMID: 36507975 DOI: 10.1007/s10067-022-06462-y]

13 **Hu Z**, Gao R, Huang W, Wang H, Qin L. Effect of Hydroxychloroquine on Lupus Activity, Preeclampsia and Intrauterine Growth Restriction in Pregnant Women with Systemic Lupus Erythematosus and/or Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis. *J Clin Med* 2023; **12** [PMID: 36675415 DOI: 10.3390/jcm12020485]

14 **Bouariu A**, Gică N, Ciobanu AM, Scutelnicu AM, Popescu MR, Panaitescu AM. The Potential Benefit of Hydroxychloroquine in Chronic Placental Inflammation of Unknown Etiology Associated with Adverse Pregnancy Outcomes. *Healthcare (Basel)* 2022; **10** [PMID: 35052331 DOI: 10.3390/healthcare10010168]

15 **Cornish EF**, McDonnell T, Williams DJ. Chronic Inflammatory Placental Disorders Associated With Recurrent Adverse Pregnancy Outcome. *Front Immunol* 2022; **13**: 825075 [PMID: 35529853 DOI: 10.3389/fimmu.2022.825075]

16 **Brady CA**, Williams C, Batra G, Church E, Tower CL, Crocker IP, Heazell AEP. Immunomodulatory Therapy Reduces the Severity of Placental Lesions in Chronic Histiocytic Intervillositis. *Front Med (Lausanne)* 2021; **8**: 753220 [PMID: 34733868 DOI: 10.3389/fmed.2021.753220]

17 **Choi EY**, Jeong HE, Noh Y, Choi A, Yon DK, Han JY, Sung JH, Choe SA, Shin JY. Neonatal and maternal adverse outcomes and exposure to nonsteroidal anti-inflammatory drugs during early pregnancy in South Korea: A nationwide cohort study. *PLoS Med* 2023; **20**: e1004183 [PMID: 36848338 DOI: 10.1371/journal.pmed.1004183]

18 **Farhan FS**, Nori W, Al Kadir ITA, Hameed BH. Can Fetal Heart Lie? Intrapartum CTG Changes in COVID-19 Mothers. *J Obstet Gynaecol India* 2022; **72**: 479-484 [PMID: 35634476 DOI: 10.1007/s13224-022-01663-6]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** April 13, 2023

**First decision:** July 4, 2023

**Article in press:** July 24, 2023

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Iraq

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Ait Addi R, Morocco; He Z, China; Mahmoud MZ, Saudi Arabia **S-Editor:** Qu XL **L-Editor:** A **P-Editor:** Xu ZH



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**